Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 657.80

+1.7%

Nov 7 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: DewDiligence_on_SI who wrote (3099)	9/28/2020 5:46:42 PM
From: Miljenko Zuanic	Read Replies (1) of 3557

<Twenty-eight percent of patients had incomplete aggregation of GB-102 and had bioabsorbable particles enter the anterior chamber of the eye. This was self-limited and reversible with no long-term sequelae.The incomplete aggregation led to optimization of GB-102 to reduce particle dispersion in the phase 2b ALTISSIMO clinical trial. This randomized study will compare 1 mg and 2 mg doses of GB-102 administered every 6 months to aflibercept every 2 months, with the objective to determine the optimal dose to evaluate in a global phase 3 program.> https://www.retinalphysician.com/issues/2020/march-2020/sustained-release-sunitinib-malate-for-neovascular

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next